Jul 23, 2026 04:26PM
Jul 23, 2026 04:26PM
Jul 21, 2026 08:00AM
Jul 21, 2026 08:00AM
Jul 10, 2026 08:00AM
Nov 6, 2025 08:00AM
Aug 14, 2025 08:00AM VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update
Jul 31, 2025 02:26AM
Jul 3, 2025 06:49AM
Jul 2, 2025 07:45AM
Jul 2, 2025 07:45AM
May 8, 2025 08:00AM
Apr 28, 2025 07:10AM
Apr 25, 2025 08:02AM VYNE Therapeutics (VYNE) Reports Clinical Hold on VYN202 Program
Apr 25, 2025 08:00AM
Jan 6, 2025 07:30AM
Jun 5, 2024 08:00AM
May 6, 2024 08:01AM
May 6, 2024 08:00AM
May 1, 2024 08:00AM
Feb 29, 2024 08:00AM VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
Feb 27, 2024 08:00AM
Jan 10, 2024 08:03AM
Jan 10, 2024 08:00AM
Oct 30, 2023 07:01AM
Oct 30, 2023 07:00AM
Mar 30, 2023 07:45AM
Mar 30, 2023 07:45AM VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201
Mar 9, 2023 04:01PM
Feb 15, 2023 08:05AM
Feb 15, 2023 08:00AM
Jan 9, 2023 04:01PM
Nov 17, 2022 08:00AM
Jun 17, 2022 08:00AM
Apr 7, 2022 08:00AM VYNE Therapeutics (VYNE) Reports Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
Apr 7, 2022 08:00AM
Mar 30, 2022 08:00AM
Mar 17, 2022 08:00AM
Mar 7, 2022 07:03AM
Mar 7, 2022 07:00AM
Jan 19, 2022 08:00AM
Jan 19, 2022 08:00AM VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
Jan 13, 2022 09:27AM
Jan 13, 2022 07:02AM
Jan 13, 2022 07:00AM
Nov 10, 2021 07:30AM
Nov 4, 2021 08:00AM
Oct 26, 2021 08:00AM
Oct 21, 2021 08:00AM VYNE Therapeutics Announces Formation of Scientific Advisory Board
Oct 19, 2021 08:00AM

326,538 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All